Janssen in Belgium sets the tone in the area of Research & Development. The largest R&D center for small molecules within the entire world-wide Janssen Group is located here. In Belgium alone, this center employs some 1,800 people in the field of Research & Development (R&D).
The R&D activities are primarily focused on the therapeutic domains of neuroscience, oncology and infectious diseases. The goal of Research & Development is the discovery and development of innovative medicines which relieve patient suffering and provide solutions for some of the most important medical needs of our time. In addition, there is the new Janssen Global Public Health Group which was established in August of 2013 and which strives, in a sustainable manner, to increase accessibility to medicines for infectious diseases such as AIDS, tuberculosis and neglected tropical diseases in countries with little means but great medical needs.
Daily, the company and its partners focus their efforts on the discovery and development of a new generation of small molecules in the domains of schizophrenia, depression, pain management, dementia, hepatitis, HIV and various types of cancer, among others. In order to tackle these great medical challenges, the research and development of valuable innovative medicines must be eagerly stimulated and promoted as an answer to the medical needs of all patients. Today's increasing knowledge and collaborations provide R&D with new chances for innovative solutions.
In 2013, the research in Belgium concentrated on substances for the treatment of schizophrenia and resistant depression, among others.
The organization practices precision medicine and alters the field of disease research by investing in first-class research competencies in the areas of biotechnology, genome theory, biomarkers, bioinformatics and so much more. The discovery of high-quality and innovative candidate medicines is indeed a complex process which requires a perfect match of top talent and the best technologies. Ethical pharmaceutical research and the responsible use of experimental animals are key to this process. Furthermore, the company is committed to safety in research and to innovation in clinical research.
In 2013, the research in Belgium concentrated on substances for the treatment of schizophrenia and resistant depression, among others. Several important milestones were also reached in the research into substances for use by our sister companies in the areas of cardiovascular disorders, infectious diseases and oncology. In 2013, 45 new patent applications were submitted by Janssen Pharmaceutica NV.
Our world-wide organization is planning the registration of 10 new molecular entities for approval between 2013 and 2017 and more than 25 additional extensions to its commercialized product lines. In 2013, the total R&D expenditures came to 1.165 million euros.